Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
Many people from Mongolia are affected by liver conditions called hepatitis B, C, and Delta. These viruses can cause serious problems, including liver cancer, but often show no symptoms, meaning people don't know they have them. In Mongolia, these conditions are quite common, and studies have shown similar rates in Mongolian communities abroad. This research project will offer free health checks to Mongolian people living in France to see if they have these types of hepatitis. The main goal is to find those affected early, offer them proper medical care, and treat the conditions to prevent severe liver damage and improve their health. This is particularly important for groups who might find it hard to access healthcare.
At a glance
What is this study about?
This study focuses on a serious health issue: viral hepatitis types B, C, and Delta. These are infections that affect the liver. In Mongolia, these conditions are very common and can lead to severe health problems, including liver cancer, which is a big concern in the country. Many people don't even know they have these viruses because they often don't cause any symptoms.
Because these conditions are silent but serious, it's really important to find people who have them through screening, which means doing checks even if someone feels well. Once diagnosed, there are treatments available that can help control the viruses, reduce the risk of liver damage, and improve long-term health. The research team knows that there's a large community of Mongolian people living in France, and similar studies in other countries have shown high rates of hepatitis B and Delta in this community.
The main aim of this study is to reach out to the Mongolian community in France and offer free screening tests for these types of hepatitis. After testing, anyone found to have these conditions will be guided towards the right medical care and treatment. This project is vital because it helps fill a gap in healthcare for a group that might face challenges accessing these important health services.
Key takeaways
- Hepatitis B, C, and Delta are common among people from Mongolia and can be serious.
- These conditions often have no symptoms, so screening is crucial.
- This study offers free screening in France for Mongolian individuals.
- Early diagnosis and treatment can prevent severe liver problems.
- The study aims to help participants access ongoing medical care if needed.
Who may be eligible?
To join this study, participants must be of Mongolian heritage and currently living in France. You need to be at least 15 years old. If you are under 18, your parent or guardian will need to give their permission for you to take part.
However, you cannot join the study if you are already seeing a doctor for hepatitis B, C, or Delta, or if you have already received treatment for these conditions. Also, you can't participate if you're in prison or under certain legal protective measures (like guardianship). If you are already involved in another medical study that might affect this one, you might also not be able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you of Mongolian heritage?
- Do you currently live in France?
- Are you 15 years old or older?
- Have you NOT been diagnosed or treated for hepatitis B, C, or Delta before?
- Are you NOT currently involved in another medical study that might affect this one?
What does participation involve?
If you decide to take part in this study, it would involve screening for hepatitis B, C, and Delta. This would likely include having some blood tests to check for these viruses. There won't be any specific medication given as part of the study itself. The study's main purpose is to identify people with these conditions and then help them get into regular care within the French healthcare system for diagnosis and treatment if needed. The total duration of your direct involvement in the screening part of the study would be short, likely focusing on the initial tests.
Potential risks and benefits
Locations (11)
- Centre Hospitalier Annecy GenevoisVerified postcodeAnnecy, France
- Centre Expert Hépatites Virales Aquitaine, CHU de BordeauxVerified postcodeBordeaux, France
- CHU de Clermont FerrandVerified postcodeClermont-Ferrand, France
- Hôpital Henri Mondor - Assistante Publique Hopitaux de Paris (APHP)Verified postcodeCréteil, France
- CHU Grenoble AlpesVerified postcodeGrenoble, France
- CHRU LilleVerified postcodeLille, France
- Service d'Hépatologie, Institut d'hépatologie de Lyon, Hôpital Croix-Rousse, Hospices Civils de LyonVerified postcodeLyon, France
- CHRU Rennes PontchaillouVerified postcodeRennes, France
- CHU de RouenVerified postcodeRouen, France
- Hôpitaux Universitaires de StrasbourgVerified postcodeStrasbourg, France
- CHRU BretonneauVerified postcodeTours, France
Common questions
What is hepatitis?
Hepatitis means inflammation of the liver, often caused by viruses. Types B, C, and Delta can cause long-term problems, including liver damage and cancer.
Why is this study focused on Mongolians?
Hepatitis B, C, and Delta are very common in Mongolia, and studies elsewhere show similar prevalence in Mongolian communities, making focused screening important.
Will I get free treatment if I have hepatitis?
The study will help you access the French healthcare system for diagnosis and ongoing care for hepatitis if you are found to have it.
Do I need to be ill to join?
No, you don't need to feel ill. These conditions often have no symptoms, which is why screening is so important to find them early.
What happens with my personal information?
Your personal information will be kept private and used only for this research, following strict rules for confidentiality and data protection.
How to find out more
François BAILLY, Dr
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.